User profiles for Kwan Ho Tang
 | Kwan Ho TangNYU School of Medicine Verified email at nyulangone.org Cited by 3918 |
[PDF][PDF] CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation
Tumor-initiating cells (T-ICs) are a subpopulation of chemoresistant tumor cells that have
been shown to cause tumor recurrence upon chemotherapy. Identification of T-ICs and their …
been shown to cause tumor recurrence upon chemotherapy. Identification of T-ICs and their …
Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations
Recent efforts in our study of cancer stem cells (CSC) in hepatocellular carcinoma (HCC) have
led to the identification of CD133 as a prominent HCC CSC marker. Findings were based …
led to the identification of CD133 as a prominent HCC CSC marker. Findings were based …
[PDF][PDF] miR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1
A novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells
within a tumor, called tumor-initiating cells (TICs) or cancer stem cells (CSCs). Here we …
within a tumor, called tumor-initiating cells (TICs) or cancer stem cells (CSCs). Here we …
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells.
However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells …
However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells …
[PDF][PDF] CD133+ liver tumor‐initiating cells promote tumor angiogenesis, growth, and self‐renewal through neurotensin/interleukin‐8/CXCL1 signaling
A novel theory in the field of tumor biology postulates that cancer growth is driven by a
population of stem‐like cells, called tumor‐initiating cells (TICs). We previously identified a TIC …
population of stem‐like cells, called tumor‐initiating cells (TICs). We previously identified a TIC …
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRAS G12C -GDP and react with …
longtime goal. Recently, inhibitors were developed that bind KRAS G12C -GDP and react with …
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Adaptive resistance to MEK inhibitors (MEKi) typically occurs via induction of genes for different
receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same histotype…
receptor tyrosine kinases (RTK) and/or their ligands, even in tumors of the same histotype…
[PDF][PDF] Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma
Identification of therapeutic targets against tumor‐initiating cells (TICs) is a priority in the
development of new therapeutic paradigms against cancer. We enriched a TIC population …
development of new therapeutic paradigms against cancer. We enriched a TIC population …
A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer
Tumor-initiating cells (TIC), also known as cancer stem cells, are regarded widely as a specific
subpopulation of cells needed for cancer initiation and progression. TICs have yet to be …
subpopulation of cells needed for cancer initiation and progression. TICs have yet to be …
[HTML][HTML] CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients
Chromodomain helicase/ATPase DNA binding protein 1–like gene (CHD1L) is a recently
identified oncogene localized at 1q21, a frequently amplified region in hepatocellular …
identified oncogene localized at 1q21, a frequently amplified region in hepatocellular …